PAPatrick Arveux

Patrick Arveux

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patrick Arveux has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Breast cancer in men in Cote d'Or (France): epidemiological characteristics, treatments and prognostic factors

    by T.S. Dabakuyo, O. Dialla, J. Gentil, M.-L. Poillot, P. Roignot, J. Cuisenier, P. Arveux

    Breast cancer in men is rare, and clinical trials are thus not feasible. This study aimed to describe the epidemiological characteristics, treatment and prognostic factors of breast cancer in men. A population-based study was performed using data from the Cote d'Or breast and gynaecological cancer registry. Data on male breast cancer diagnosed from 1982 to 2008 were provided. Relative survival rates were estimated at 5 years according to the characteristics of the patient and tumour, and treatment. Prognostic factors of survival in men with breast cancer were identified using a generalised linear model. Seventy-five men with invasive breast cancer were registered. Mean age at diagnosis was 66 years. The use of adjuvant chemotherapy (P= 0.013) and hormone therapy (P < 0.0001) increased over time. Relative survival rate at 5 years was 69% for the whole population. Analysis of relative survival according to the treatment showed that survival was longer for patients treated with surgery + radiotherapy + hormone therapy: 89% at 5 years. Scarff, Bloom and Richardson grade was independent prognostic factor of survival. Male breast cancer is a rare disease with a poor prognosis, and diagnosis is often made at an advanced stage. Early diagnosis and better knowledge of the disease would certainly lead to improvements in the prognosis.


  • Modelling the effect of breast cancer screening on related mortality using French data

    by Z. Uhry, G. Hédelin, M. Colonna, B. Asselain, P. Arveux, C. Exbrayat, C. Guldenfelds, P. Soler-Michel, F. Molinié, B. Trétarre, et al.


  • Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test

    by Catherine Lejeune, Vincent Dancourt, Patrick Arveux, Claire Bonithon-Kopp, Jean Faivre

    Objectives: The aim of this study was to compare the cost and the effectiveness of two biennial fecal occult blood screening tests for colorectal cancer: a guaiac nonrehydrated test (G-FOBT) and an immunochemical test (I-FOBT) with the absence of screening.Methods: A Markov model was developed to compare these strategies in a general population of subjects aged 50 to 74 over a 20-year period.Results: Compared with the absence of screening, G-FOBT and I-FOBT were associated with a decrease in colorectal cancer mortality of 17.4 percent and 25.2 percent, respectively. With regard to cost-effectiveness, expressed as cost per life-year gained, I-FOBT was the most effective and most costly alternative. Compared with no screening, G-FOBT and I-FOBT presented similar discounted incremental cost-effectiveness ratios: €2,739 and €2,819 respectively per life-year gained. When compared with G-FOBT, I-FOBT presented an incremental cost-effectiveness ratio of €2,988 per life-year gained. Sensitivity analyses showed the strong influence of the I-FOBT lead time, of the participation rate to screening for I-FOBT, and of the purchase price of the I-FOBT on the discounted incremental cost-effectiveness ratios.Conclusions: Compared with the absence of screening and with G-FOBT, the biennial two-stool immunochemical test can be considered a promising method for mass screening for colorectal cancer.


  • Open Access

    Does the availability of positron emission tomography modify diagnostic strategies for solitary pulmonary nodules? An observational study in France

    by Irawati Lemonnier, Cédric Baumann, Nicolas Jay, Kazem Alzahouri, Patrick Arveux, Damien Jolly, Catherine Lejeune, Michel Velten, Fabien Vitry, Marie-Christine Woronoff-Lemsi, et al.

    Background: Previous studies showed that at the individual level, positron emission tomography (PET) has some benefits for patients and physicians in terms of cancer management and staging. We aimed to describe the benefits of (PET) in the management of solitary pulmonary nodules (SPNs) in a population level, in terms of the number of diagnostic and invasive tests performed, time to diagnosis and factors determining PET utilization. Methods: In an observational study, we examined reports of computed tomography (CT) performed and mentioning "spherical lesion", "nodule" or synonymous terms. We found 11,515 reports in a before-PET period, 2002–2003, and 20,075 in an after-PET period, 2004–2005. Patients were followed through their physician, who was responsible for diagnostic management. Results: We had complete data for 112 patients (73.7%) with new cases of SPN in the before-PET period and 250 (81.4%) in the after-PET period. Patients did not differ in mean age (64.9 vs. 64.8 years). The before-PET patients underwent a mean of 4 tests as compared with 3 tests for the after-PET patients (p = 0.08). Patients in the before-PET period had to wait 41.4 days, on average, before receiving a diagnosis as compared with 24.0 days, on average, for patients in the after-PET period who did not undergo PET (p < 0.001). In the after-PET period, 11% of patients underwent PET during the diagnostic process. A spiculated nodule was more likely to determine prescription for PET (p < 0.001). Multivariate analysis revealed that patients in both periods underwent fewer tests when PET was prescribed by general practitioners (p < 0.001) and if the nodule was not spiculated (p < 0.001). The proportion of unnecessary invasive approaches prescribed (47% vs. 49%) did not differ between the groups. Conclusion: In our study, 1 year after the availability of PET, the technology was not the first choice for diagnostic management of SPN. Even though we observed a tendency for reduced number of tests and mean time to diagnosis with PET, these phenomena did not fully relate to PET availability in health communities. In addition, the availability of PET in the management of SPN diagnosis did not reduce the overall rate of unnecessary invasive approaches.


  • Open Access

    Management of SPN in France. Pathways for definitive diagnosis of solitary pulmonary nodule: a multicentre study in 18 French districts

    by Kazem Alzahouri, Michel Velten, Patrick Arveux, Marie-Christine Woronoff-Lemsi, Damien Jolly, Francis Guillemin

    The process of diagnosis and management of solitary pulmonary nodules (SPNs) between 1 and 3 cm is not standardized. This multicentre study investigated how diagnosis of newly discovered SPNs is managed in routine practice. We examined 11,515 radiology reports of patients undergoing chest computed tomography (CT) at all 76 radiology centres in 18 French administrative districts covering 8,220,000 people. Information on diagnostic procedures and treatment administered from discovery to definitive diagnosis of SPN was collected prospectively. We identified 152 cases of newly diagnosed SPNs. Follow-up was complete for 112 patients. The median number of diagnostic tests was 4 and the mean time to diagnosis was 41.4 days. Marked variability was observed in the sequence of diagnostic tests, and 8 diagnostic pathways were identified. Patients' characteristics and radiological features of SPNs influenced the number of tests performed. Referral by specialist, history of smoking and spiculated SPN predicted the performance of at least one invasive procedure (P < 0.01). Definitive diagnosis was a malignant disease in 30 patients (26%). The diagnosis of SPN is a complex process that physicians approach in markedly different ways. Implementing practice guidelines for managing the diagnosis of SPN requires clarification.


  • Open Access

    The influence of socio-economic and surveillance characteristics on breast cancer survival: a French population-based study

    by J Gentil-Brevet, M Colonna, A Danzon, P Grosclaude, G Chaplain, M Velten, F Bonnetain, P Arveux


  • Open Access

    Population-based study of breast cancer survival in Cote d’Or (France): prognostic factors and relative survival

    by T. S. Dabakuyo, F. Bonnetain, P. Roignot, M.-L. Poillot, G. Chaplain, T. Altwegg, G. Hedelin, P. Arveux

    Background: Few population-based studies have reported jointly analyses of relative survival according to the following prognostic factors: tumour–node–metastasis (TNM) stage, age, number of examined and positive nodes, hormonal status, histological Scarff, Bloom and Richardson (SBR) grade, tumour extension, hormone receptor status and tumour multifocal status. Patients and methods: Data on female invasive breast cancer were provided by the Cote d'Or breast cancer registry. The Kaplan–Meier method and log-rank test were used to estimate and compare the survival probability at 1, 5, 10 and 15 years. The effect of prognostic factors on survival was assessed with crude and relative multivariate survival analyses. Results: Crude survival seemed to be worse in patients aged >60 years compared with those aged 45–60 (P > 0.0001), whereas relative survival did not differ. TNM stage, histological SBR grade, progesterone receptor status, tumour multifocal status, locoregional extension and the period of diagnosis were independent prognostic factors of crude and relative survival. Conclusion: Breast cancer is influenced by many factors. Despite the absence of any association between the number of examined nodes and overall survival in this study, the number of nodes removed, in conjunction with other prognostic factors, may be useful in selecting node-negative patients for systemic therapy.


  • Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA)

    by F. Bonnetain, O. Bouche, J.-L. Raoul, M. Giovannini, P.-L. Etienne, L. Bedenne, J.-F. Seitz, G. Lledo, T. Conroy, P. Arveux

    4150 Background: The results of a randomized phase II trial in pts with MGA showed that LV5FU2-irinotecan (CPT arm) combination as first-line therapy had a better efficacy and toxicity profile than LV5FU2 (5FU arm) alone or LV5FU2-cisplatin (CIS arm) (Bouché et al. Proc ASCO 2003; 22: 258). QoL was assessed using the EORTC QLQ-C30 to investigate the risk-benefit ratio and to test the infrastructure for future data collection before a phase III study. Methods: QLQ-C30 was self-administered at baseline and every 8 weeks in the 134 eligible pts: 5FU arm (45 pts), CIS (44 pts) and CPT (45 pts). Scores were compared to baseline with an analysis of variance (ANOVA). During a 6-month follow-up: - QLQ C30 scores and compliance were analyzed with mean (SD) and percent of missing scores; - a mixed ANOVA model for repeated measurements was applied to summarize the better longitudinal QoL profile. The same analyses were performed with the extreme poorest QLQ-C30 allocation for non-ignorable missing scores. Results: Compliance decreased with time: missing scores for global QoL increased from 18% (5FU arm), 25% (CIS arm), 16% (CPT arm) at baseline to 59%, 62% and 52% at 6 months respectively. At inclusion, 5FU arm pts reported more constipation than in CIS arm or CPT (p 5 points); 2 - the poorest allocation analysis showed a QoL deterioration whatever the treatment, however 14 QLQ-C30 scores were better in CPT arm than in 5FU arm (4 scales with MD > 5 points) and 15 scores were better in the CPT arm than CIS arm (14 scales with MD > 5 points). Conclusion: Although QoL variability at inclusion and missing data represent a limitation, this study shows a favourable impact of LV5FU2-irinotecan on QoL during the 6-month study period and confirms its better risk-benefit ratio in 1st line MGA. Supported by Aventis, Baxter and the ARC No significant financial relationships to disclose.